JACI-35.054
- Generic Name
- JACI-35.054
A Study to Evaluate the Safety, Tolerability and Immunogenicity of Tau Targeted Vaccines in Participants With Early Alzheimer's Disease
Phase 1
Completed
- Conditions
- Cognitive ImpairmentMild Cognitive ImpairmentDementiaBrain DiseasesAlzheimer's DiseaseTauopathiesCentral Nervous System Diseases
- Interventions
- First Posted Date
- 2020-06-24
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- AC Immune SA
- Target Recruit Count
- 57
- Registration Number
- NCT04445831
- Locations
- 🇫🇮
Clinical Research Services Helsinki, Helsinki, Finland
🇬🇧University College London Hospitals NHS Foundation Trust, London, United Kingdom
🇸🇪Minnesmottagningen - Sahlgrenska Universitetssjukhuset - Mölndal Sjukhus, Mölndal, Sweden
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath